Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(20):1443; doi:10.1093/jnci/djj448
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Epigenetic Inhibitors

The first 10% of the full text of this article appears below.


 Inhibitor        Alternate Name        State of Development      
 DNA Methyltransferase Inhibitors                      
 5-azacytidine        Azacitidine, Vidaza        FDA approved for myelodysplastic syndromes (MDS)      
 5-aza-2'-deoxycytidine        Decitabine, Dacogen        FDA approved for MDS      
 Arabinosyl-5-azacytidine        Fazarabine        Phase I/II      
 5-6-dihydro-5-azacytidine        DHAC        Phase I/II      
 5-fluoro-2'-deoxycytidine                Phase I/II      
 EGX30P        Oligonucleotide              
 Epigallocatechin-3-Gallate        EGCG              
 MG98        DNMT1 Antisense        Phase II      
 RNAi                      
 Zebularine                Preclinical      
 RG108                Preclinical      
 Histone Deacetylase Inhibitors                      
 Apicidin                      
 Butyrates        Phenylbutyrate, Buphenyl        FDA approved for urea cycle disorders      
 m-Carboxycinnamic acid bishydroxamide (CBHA)        CBHA              
 Cyclic hydroxamic-acid-containing peptide 1        CHAP1              
 Depudecin        Epoxide              
 FK228        Depsipeptide, FR901228        Phase I/II      
 MS-275        Benzamidine        Phase I      
 LAQ824                Phase I      
 Oxamflatin                      
 MGCD0103                Phase I/II      
 PXD101                Phase I      
 Pyroxamide                Phase I      
 RNAi                      
 Suberic Bishydroxamic Acid        SBHA              
 Suberoylanilide Hydroxamic Acid        SAHA,vorinostat, Zolinza        Under FDA review for CTCL      
 Trichostatin A        TSA              
 Trapoxin A                      
 Valproic Acid        Depakote, Depakene        FDA approved Anti-Seizure Drug      

Compiled by . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?